| Trial ID: | L3988 |
| Source ID: | NCT04495881
|
| Associated Drug: |
Sitagliptin 100mg
|
| Title: |
Sitagliptin for the Treatment of Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Sitagliptin 100mg
|
| Outcome Measures: |
Primary: HbA1c change, Changes in HbA1c from baseline at 1 month and 3 months during follow-up, Changes in HbA1c from baseline at 1 month and 3 months during follow-up | Secondary: fasting blood glucose change, Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up, Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up|HOMA-IR change, Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up, Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up|Glycated Albumin（GSA）change, Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up, Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up
|
| Sponsor/Collaborators: |
Sponsor: Beijing Chao Yang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2020-01-01
|
| Completion Date: |
2025-09-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-07-28
|
| Locations: |
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT04495881
|
